Osteoarticular Infections With Pneumococcal

Overview

Osteoarticular infections at pneumococcal are rare, potentially serious and remain under diagnosed. They represent 3 at 10% of the arthritis septic in the literature. 190 cases have been published of 1965 at 2003. They represent 0.3% at 0.6% of the bacteraemia at Streptococcus peumoniae.

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Retrospective
• Study Primary Completion Date: March 1, 2019

Interventions

• Other: Bone and joint infection with Streptococcus peumoniae
  • description of the osteoarticular infection with Streptococcus peumoniae

Arms, Groups and Cohorts

• Bone and joint infection with Streptococcus peumoniae
  • Patients having had an osteoarticular infection with Streptococcus peumoniae

Clinical Trial Outcome Measures

Primary Measures

• Description and rate of bone or joint infection with S. pneumoniae
  • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
  • Description of the type of infection due to S. pneumoniae : patients and type of implant, profile of the bacterium associated in the infection, medical and chirurgical treatment

Secondary Measures

• Rate of Treatment Failure
  • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
  • Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Participating in This Clinical Trial

Inclusion Criteria

• patients having had a bone and joint infection with S pneumoniae, with or without device. Exclusion Criteria:

• none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Investigator Details

• Lead Sponsor
  • Hospices Civils de Lyon
• Provider of Information About this Clinical Study
  • Principal Investigator: Eugénie MABRUT, clinical reserach assistant – Hospices Civils de Lyon
• Overall Official(s)
  • Tristan Ferry, Md,PhD, Study Director, Hospices Civils de Lyon